Cardiomyopathy and Stroke

Hypertrophic cardiomyopathy (HCM) is most likely to develop in patients with ischemic stroke (IS), mortality, cardiovascular death, all strokes, and major cardiovascular events, such as ventricular arrhythmias leading to cardiac arrest and rehospitalisation for heart failure.
• Using a complex weighted score that considers variables like age, the presence of AF, the age at which AF first manifested, prior thromboembolism, New York Heart Association class, left atrial size, mean wall thickness, and vascular disease, the HCM Risk-CVA (cerebrovascular accident) score can be used to predict IS.

 

    Related Conference of Cardiomyopathy and Stroke

    November 27-28, 2025

    32nd World Heartcare Summit

    Paris, France
    January 12-13, 2026

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2026

    15th World Heart Congress

    Paris, France
    March 23-24, 2026

    41st World Cardiology Conference

    London, UK
    April 08-29, 2026

    9th Annual Heart Rhythm Conference

    Vienna, Austria
    April 13-14, 2026

    9th World Heart and Brain Conference

    Tokyo, Japan
    May 14-15, 2026

    5th International Conference on Cardiology

    Rome, Italy
    May 21-22, 2026

    15th World Congress on Cardiology

    London, UK
    July 29-30, 2026

    30th World Cardiology Conference

    Paris, France

    Cardiomyopathy and Stroke Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in